- Home
- SLI vs BHVN Comparison
SLI vs BHVN Comparison
Compare SLI & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLI | BHVN |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | SLI | BHVN |
|---|---|---|
| Price | $4.22 | $11.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 15 |
| Target Price | $5.25 | ★ $30.36 |
| AVG Volume (30 Days) | ★ 3.4M | 2.7M |
| Earning Date | 11-10-2025 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.08 | $7.48 |
| 52 Week High | $6.40 | $44.28 |
Technical Indicators
Market Signals| Indicator | SLI | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 42.10 | 49.83 |
| Support Level | $3.97 | $10.61 |
| Resistance Level | $4.42 | $13.08 |
| Average True Range (ATR) | 0.40 | 0.79 |
| MACD | -0.10 | -0.07 |
| Stochastic Oscillator | 12.07 | 34.15 |
Price Performance
Historical ComparisonAbout SLI Standard Lithium Ltd.
Standard Lithium Corp is engaged in the exploration and development of lithium brine properties in the United States. The company is focused on the exploration and development of the Arkansas Lithium Project, which is located in south-central Arkansas. Its other projects comprise the Lanxess Project, and Bristol Dry Lake Project.
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.